Navigation Links
Asthma Drug May Help Those With Chronic Hives
Date:7/22/2014

By
HealthDay Reporter

MONDAY, July 21, 2014 (HealthDay News) -- A drug already used to treat moderate-to-severe allergic asthma appears to offer relief to people with chronic hives who haven't been helped by standard medications, new research suggests.

The prescription drug -- omalizumab (Xolair) -- is already available to treat hives, following U.S. Food and Drug Administration approval earlier this year for that use.

The current study confirms that when Xolair is taken at a high dose for a six-month period it seems to be both safe and effective at controlling the severe and often debilitating itching that characterizes long-term hives.

"So what we're talking about here are only chronic cases, in which patients have hives that last for more than six weeks," explained study senior author Dr. Karin Rosen, an associate group medical director with Genentech Inc., in San Francisco. "That's usually just .5 to 1 percent of hives patients."

"But for those patients, this is a really horrible disease," she noted. "And until now antihistamines have been the only approved drug for chronic hives. But to work, antihistamines often need to be used at up to four times approved levels, which has a sedating effect. And 50 percent of the time patients didn't respond anyway."

"So then," said Rosen, "they would try other types of medications, like systemic steroids. But over time steroids can have very severe side effects. So then we would turn to the heavy artillery, like [the immunosuppressant drug] cyclosporine, which also has very severe side effects, and can't be taken by people with high blood pressure or heart disease."

"All this means that many, many patients have simply been left without any treatment," she noted. "But with this drug we are seeing great improvement in patients who previously had no options. And that's very, very encouraging."

Rosen and her colleagues discuss their findings in the July 21 issue of the Journal of Investigative Dermatology. The current study is the latest in a series of ongoing studies, which are being funded by drug manufacturer Genentech Inc. and Novartis Pharma AG in Basel Switzerland.

While not lethal, chronic hives can last for months, and tend to come and go without a clear idea of what brings it on. And, Rosen noted that almost half of chronic hive patients also have angioedema, a "scary and deforming" condition that involves deep tissue swelling, often affecting the eyes and the tongue.

To explore Xolair's potential, the team tested its effectiveness among more than 260 chronic hives patients for whom prior treatment had failed.

Patients were randomly divided into four groups, in which they were respectively treated with a once-a-month injection of Xolair at either a 75 milligram (mg) dose, a 150 mg dose, a 300 mg dose, or a dummy shot.

Tracking was conducted for both a three-month period and a six-month period.

The team found that by the 12th week, people given Xolair showed a marked reduction in their overall number of hives, hive intensity and itching severity, compared with patients who got the dummy treatment. And Rosen noted that roughly 40 percent saw a complete disappearance of all symptoms, while 80 percent experienced "what we call minimally important improvement."

Symptom relief was maintained through the six-month mark, and the authors determined that those treated with the highest (300 mg) dosage of Xolair saw the biggest improvement.

Side effects were described as being mild to moderate, and included headaches, joint pain, sinus infection and reactions at the point of injection.

The study authors acknowledged that more research will be needed to see how the drug performs over longer periods of time.

Dr. Robert Kirsner, chair of the department of dermatology and cutaneous surgery and chief of dermatology at the University of Miami Miller School of Medicine, suggested that the new intervention could prove to be a boon for a condition that "can significantly affect patients' quality of life."

"Patients suffer from this severe, recurrent itching, and it is a challenge for clinicians to find treatments that can help," he noted. "The data related to omalizumab use, in a well-performed randomized clinical trial, is extremely promising and offers hope for patients who have chronic [hives], and for the physicians who care for them."

More information

Visit the Asthma and Allergy Foundation of America for more on hives.

SOURCES: Karin Rosen, M.D., Ph.d., associate group medical director, Genentech, Inc., San Francisco; Robert Kirsner, M.D., Ph.D., professor, vice chairman and chair, department of dermatology and cutaneous surgery, and chief, dermatology, University of Miami Miller School of Medicine, Miami; July 21, 2014, Journal of Investigative Dermatology


'/>"/>
Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Rapid Asthma Treatment in ER May Prevent Admission
2. Some Schools Dont Let Kids Carry Asthma Inhalers
3. Secondhand smoke continues to vex children with asthma
4. Many Asthmatic Kids Harmed by Secondhand Smoke: Study
5. Seniors Undertreated for Asthma, and Many Skip Inhalers: Study
6. ICU stays for worst asthma drop 74 percent, review finds
7. Inhaled Steroids Lead to Big Drop in Asthma Deaths at Texas Hospital: Study
8. Asthma Cases Continue to Rise in U.S., Affecting Millions
9. Prenatal exposure to pollution especially dangerous for children with asthma
10. Breathing Smog While Pregnant May Worsen Asthma in Offspring
11. Identifying asthma patients who tolerate lower doses of steroids remains problematic
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Asthma Drug May Help Those With Chronic Hives
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology: